Rennova Health Inc (NASDAQ:RNVA) has announced an agreement with its subsidiary Advanced Molecular Services Group, Inc. and Certainty Health, LLC. Rennova Health Inc is a vertically integrated provider of leading supportive and diagonistic software solution for healthcare providers. On the other hand, Certainty Health is s provider of cloud-based mobile applications for patient-focused health information. The mission behind the partnership is to develop innovative smartphone tools to allow patients, families and healthcare providers to access crucial patients’ genetic background so as to make treatment decisions for various psychiatric diseases.
Certainty Health President and COO Dr. Chris Yoo said they are expectant their partnership with Rennova Health will help his company in expanding precision medicine platform so as to address the unmet demands among patients and caregivers for molecular information affecting psychiatry. He added that Rennova has a big database of pharmacogenomic drug metabolism data spanning over a decade of real-world diagnostic results for multiple diseases.
Under the agreement, Rennova will be in charge of marketing consumer-facing genetic tests which are developed by the Advanced Molecular Services Group using the Certainty Health brand. The first product to be sold through the partnership include tests which are used to determine how an individual will respond to a variety of pharmaceutical drugs which are used in treating psychiatric disorders. According to data from the National Alliance on Mental Illness, NAMI, 43.8 million people in the U.S are being treated for psychiatric disorders plus around 66% more people can’t access the treatment according to the World Health Organization. The partnership is expected to offer the test results for the texts for the physicians, patients and other involved parties so as to deliver the right treatment to patients in the right amounts.
The collaboration will deliver test results for these patients, physicians, and other stakeholders in the circle of care team to increase the chances that the right drug will be chosen for the right patient in the right amount. According to Advanced Molecular Services Group, the molecular tests will be available by the fourth quarter of 2017. The technology produced by the group integrates patented laboratory testing results and artificial intelligence interpretation to offer treatment options for patients and their physicians.